Literature DB >> 29958247

Plasma coadministration improves resuscitation with tranexamic acid or prothrombin complex in a porcine hemorrhagic shock model.

John Kuckelman1, Morgan Barron, Donald Moe, Michael Lallemand, John McClellan, Shannon Marko, Matthew Eckert, Matthew J Martin.   

Abstract

BACKGROUND: Traumatic coagulopathy has now been well characterized and carries high rates of mortality owing to bleeding. A 'factor-based' resuscitation strategy using procoagulant drugs and factor concentrates in lieu of plasma is being used by some, but with little evidentiary support. We sought to evaluate and compare resuscitation strategies using combinations of tranexamic acid (TXA), prothrombin complex concentrate (PCC), and fresh frozen plasma (FFP).
METHODS: Sixty adult swine underwent 35% blood volume hemorrhage combined with a truncal ischemia-reperfusion injury to produce uniform shock and coagulopathy. Animals were randomized to control (n = 12), a single-agent group (TXA, n = 10; PCC, n = 8; or FFP, n = 6) or combination groups (TXA-FFP, n = 10; PCC-FFP, n = 8; TXA-PCC, n = 6). Resuscitation was continued to 6 hours. Key outcomes included hemodynamics, laboratory values, and rotational thromboelastometry. Results were compared between all groups, with additional comparisons between FFP and non-FFP groups.
RESULTS: All 60 animals survived to 6 hours. Shock was seen in all animals, with hypotension (mean arterial pressure, 44 mm Hg), tachycardia (heart rate, 145), acidosis (pH 7.18; lactate, 11), anemia (hematocrit, 17), and coagulopathy (fibrinogen, 107). There were clear differences between groups for mean pH (p = 0.02), international normalized ratio (p < 0.01), clotting time (CT; p < 0.01), lactate (p = 0.01), creatinine (p < 0.01), and fibrinogen (p = 0.02). Fresh frozen plasma groups had significantly improved resuscitation and clotting parameters (Figures), with lower lactate at 6.5 versus 8.4 (p = 0.04), and increased fibrinogen at 126 versus 95 (p < 0.01). Rotational thromboelastometry also demonstrated shortened CT at 60 seconds in the FFP group vs 65 seconds in the non-FFP group (p = 0.04).
CONCLUSION: When used to correct traumatic coagulopathy, combinations of FFP with TXA or PCC were superior in improving acidosis, coagulopathy, and CT than when these agents are given alone or in combination without plasma. Further validation of pure factor-based strategies is needed.

Entities:  

Mesh:

Substances:

Year:  2018        PMID: 29958247     DOI: 10.1097/TA.0000000000001942

Source DB:  PubMed          Journal:  J Trauma Acute Care Surg        ISSN: 2163-0755            Impact factor:   3.313


  5 in total

1.  Prothrombin Complex Concentrate for Trauma Induced Coagulopathy: A Systematic Review and Meta-Analysis.

Authors:  Ting-Wei Kao; Yi-Chin Lee; Hsiang-Ting Chang
Journal:  J Acute Med       Date:  2021-09-01

2.  Resuscitation with whole blood or blood components improves survival and lessens the pathophysiological burden of trauma and haemorrhagic shock in a pre-clinical porcine model.

Authors:  Sarah Ann Watts; Jason Edward Smith; Thomas Woolley; Rory Frederick Rickard; Robert Gwyther; Emrys Kirkman
Journal:  Eur J Trauma Emerg Surg       Date:  2022-07-27       Impact factor: 2.374

3.  Reversing direct factor Xa or thrombin inhibitors: Factor V addition to prothrombin complex concentrate is beneficial in vitro.

Authors:  Herm Jan M Brinkman; Frauke Swieringa; Marleen Zuurveld; Alicia Veninga; Sanne L N Brouns; Johan W M Heemskerk; Joost C M Meijers
Journal:  Res Pract Thromb Haemost       Date:  2022-04-25

4.  Hemodynamic Effects of Cardiovascular Medications in a Normovolemic and Hemorrhaged Yorkshire-cross Swine Model.

Authors:  Jacob H Cole; Scott B Hughey; Phillip G Geiger; Kamala J Rapp-Santos; Gregory J Booth
Journal:  Comp Med       Date:  2021-12-07       Impact factor: 1.565

5.  Damage control orthopaedics: State of the art.

Authors:  Enrique Guerado; Maria Luisa Bertrand; Juan Ramon Cano; Ana María Cerván; Adolfo Galán
Journal:  World J Orthop       Date:  2019-01-18
  5 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.